Focus:
News
-
6 August 2020
BioNTech and Fosun Pharma trial Covid-19 vaccine in China
BioNTech and Shanghai Fosun Pharmaceutical have started dosing participants in a Phase I clinical trial of Covid-19 vaccine candidate, BNT162b1.
-
6 August 2020
Zydus Cadila’s Covid-19 vaccine enters Phase II testing
India-based Zydus Cadila has launched Phase II clinical trials of its Covid-19 vaccine candidate, ZyCoV-D, which showed promise in a Phase I study.
-
5 August 2020
Investment firm GI Partners to acquire minority interest in Clinical Ink
Private equity investment firm GI Partners has announced that it will acquire a minority interest in global clinical trial technology Clinical Ink.
-
5 August 2020
NIH starts trial of antibody treatments for Covid-19 patients
The US National Institutes of Health (NIH) has initiated a Phase III clinical trial, named ACTIV-3, to evaluate various types of monoclonal antibodies as potential treatments for hospitalised Covid-19 patients.
-
5 August 2020
Novartis’ Kymriah shows benefit in follicular lymphoma patients
Novartis has reported positive data from the Phase II ELARA clinical trial of Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL).
-
5 August 2020
COVID-19 poll: Disrupted clinical trials will take six to 12 months to return to normal
The COVID-19 pandemic significantly disrupted ongoing clinical trials in various stages, with more than 1,000 trials by sponsors, collaborators, or contract research organisations having gone off the trial schedules.
-
5 August 2020
Novavax’s Covid-19 vaccine yields positive data in Phase I trial
Novavax has reported positive Phase I results from the Phase I/II clinical trial of its Covid-19 vaccine candidate performed in healthy participants aged 18-59 years.
-
4 August 2020
CymaBay’s seladelpar meets primary endpoint in Phase III PBC trial
CymaBay Therapeutics has reported positive data from the Phase III clinical trial of seladelpar in patients with primary biliary cholangitis (PBC).
-
4 August 2020
Lilly initiates trial of neutralising antibody against Covid-19
Eli Lilly in alliance with the US National Institute of Allergy and Infectious Diseases (NIAID), has launched the Phase III BLAZE-2 clinical trial LY-CoV555 to prevent Covid-19 in residents and...
-
4 August 2020
AbbVie, Amgen and Takeda commence I-SPY COVID Trial
AbbVie, Amgen and Takeda Pharmaceutical, which are the COVID R&D Alliance members, have started patient enrolment in the I-SPY COVID Trial.